Monopar Therapeutics Sets August 5th Annual Meeting

TL;DR

Monopar's annual meeting is Aug 5th. Proxy filing is in. No fee.

AI Summary

Monopar Therapeutics Inc. filed a definitive proxy statement (DEF 14A) for its annual meeting of stockholders scheduled for August 5, 2024. The filing indicates no fee was required for this submission. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda and proposals for the annual meeting, influencing corporate governance and future strategic decisions.

Risk Assessment

Risk Level: low — This is a routine proxy filing for an annual meeting, not indicating any immediate financial or operational distress.

Key Numbers

• August 5, 2024 — Annual Meeting Date (Date for stockholders to vote on corporate matters.)

Key Players & Entities

• Monopar Therapeutics Inc. (company) — Registrant
• August 5, 2024 (date) — Annual Meeting Date
• 20240722 (date) — Filing Date

FAQ

From the Filing

0001437749-24-023123.txt : 20240722 0001437749-24-023123.hdr.sgml : 20240722 20240722070007 ACCESSION NUMBER: 0001437749-24-023123 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240805 FILED AS OF DATE: 20240722 DATE AS OF CHANGE: 20240722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 241129237 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 DEF 14A 1 mnpr20240714_def14a.htm FORM DEF 14A mnpr20240714_def14a.htm Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934(Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 MONOPAR THERAPEUTICS INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a–6(i)(1) and 0–11. Table of Contents NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held on August 5, 2024, at 10:00am Central Time Dear Stockholder: You are cordially invited to attend the Annual Meeting of Stockholders of Monopar Therapeutics Inc., a Delaware corporation (the “ Company ”), which will be held on August 5, 2024, at 10:00am Central Time at the Company’s headquarters at 1000 Skokie Blvd., Wilmette, IL 60091 (the “ Annual Meeting ”). Only stockholders who held stock at the close of business on the record date, July 12, 2024, may vote at the Annual Meeting, including any adjournment or postponement thereof. At the Annual Meeting, you will be asked to consider and vote upon: (1) the election of six directors named herein to our Board of Directors to serve until our next annual meeting of stockholders or until their respective successors are duly elected and qualified; (2) the ratification of the selection of BPM LLP as our independent registered public accounting firm for the year ending December 31, 2024; (3) To approve an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a split ratio of between 1-for-2 and 1-for-20 as determined by the Board of Directors in its sole discretion, prior to the one-year anniversary of this Annual Meeting; and (4) To approve an amendment to the Amended 2016 Stock Incentive Plan to increase the aggregate number of shares available for the grant of awards. No other items of business are expected to be considered, and no other director nominees will be entertained, at the Annual Meeting. The accompanying Proxy Statement more fully describes the details of the business to be conducted at the Annual Meeting. After careful consideration, our Board of Directors has unanimously approved the proposals and recommends that you vote FOR each of the six director nominees; FOR the ratification of the selection of BPM LLP; FOR the approval to amend the Company’s Second Amende